Commercialisation Strategies for Molecular Diagnostics

Diagnostics is a large and stable industry worth approximately $40 Billion and growing at 3-5% per annum. The continuous discovery of new gene targets and the increase in the number of validated biomarkers provides continuous innovation and opportunity in the disease diagnostic market. In addition molecular diagnostics are becoming increasingly important to the pharma industry in the move from mass market therapies to specialist therapies and the stratification of disease.

The key question for many new technology companies is how to enter and compete in this industry.

Nexxus invites you to come and hear from experienced leaders in this field who have been - and continue to be  - adept at developing and putting into play successful commercial strategies which address this question.

Speakers

Dr Stephen Little, Vice President, Personalised Healthcare, Qiagen,
‘Pioneering personalised healthcare through pharma partnering: A case study in companion diagnostic development'.

David Burns, CEO, Renishaw Diagnostics,
‘Commercialisation strategy for bringing a Multiplex Molecular (MDx) Diagnostics System to market’.

Colin King, Site Director, Axis-Shield Diagnostics
’Future Strategy for in vitro diagnostics’

To register online for this free event please follow link to the website http://www.nexxusscotland.com/events/show/1067 or contact Judy Rudd j.rudd@nexxusscotland.com